*Some Market data delayed by 15 mins.

Rigel Pharmaceuticals Inc. (New)

Symbol: RIGL (NASDAQ)
28.55 ▲ (1.54%) 0.434

Company Description:
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Key Stats
  • Today's Open: $28.04
  • Today's High: $29.433
  • Today's Low: $28.085
  • Today's Volume: 488.51K
  • Yesterday Close: $28.12
  • Yesterday High: $29.18
  • Yesterday Low: $27.75
  • Yesterday Volume: 473.60K
  • Last Min Volume: 0
  • Last Min High: $28.554
  • Last Min Low: $28.547
  • Last Min VWAP: $0
Company Profile
  • Name: Rigel Pharmaceuticals Inc. (New)
  • Website: https://www.rigel.com
  • Listed Date: 2000-11-29
  • Location: SOUTH SAN FRANCISCO, CA
  • Market Status: Active
  • CIK Number: 0001034842
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $504.40M
  • Round Lot: 100
  • Outstanding Shares: 17.94M
  • Asset Type: CS
RECENT FILINGS FOR RIGL
Filing Date Filing Type Format
2025-09-17 4 View
2025-09-17 4 View
2025-09-17 4 View
2025-09-17 4 View
2025-09-17 4 View
2025-08-14 SCHEDULE 13G/A View
2025-08-06 S-8 View
2025-08-05 SCHEDULE 13G/A View
2025-08-05 10-Q View
2025-08-05 8-K View
2025-05-28 4 View
2025-05-28 4 View
2025-05-28 4 View
2025-05-28 4 View
2025-05-28 4 View
2025-05-28 4 View
2025-05-23 8-K View
2025-05-15 SCHEDULE 13G/A View
2025-05-06 8-K View
2025-05-06 10-Q View

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.